Clinical Relevance of Liquid Biopsy in Melanoma and Merkel Cell Carcinoma - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Cancers Année : 2020

Clinical Relevance of Liquid Biopsy in Melanoma and Merkel Cell Carcinoma

(1, 2) , (1, 2) , (1, 3) , (1) , (1) , (1, 2)
1
2
3

Résumé

Melanoma and Merkel cell carcinoma are two aggressive skin malignancies with high disease-related mortality and increasing incidence rates. Currently, invasive tumor tissue biopsy is the gold standard for their diagnosis, and no reliable easily accessible biomarker is available to monitor patients with melanoma or Merkel cell carcinoma during the disease course. In these last years, liquid biopsy has emerged as a candidate approach to overcome this limit and to identify biomarkers for early cancer diagnosis, prognosis, therapeutic response prediction, and patient follow-up. Liquid biopsy is a blood-based non-invasive procedure that allows the sequential analysis of circulating tumor cells, circulating cell-free and tumor DNA, and extracellular vesicles. These innovative biosources show similar features as the primary tumor from where they originated and represent an alternative to invasive solid tumor biopsy. In this review, the biology and technical challenges linked to the detection and analysis of the different circulating candidate biomarkers for melanoma and Merkel cell carcinoma are discussed as well as their clinical relevance.
Fichier principal
Vignette du fichier
cancers-12-00960-v2.pdf (875.16 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03257721 , version 1 (11-06-2021)

Licence

Paternité - CC BY 4.0

Identifiants

Citer

Magali Boyer, Laure Cayrefourcq, Olivier Dereure, Laurent Meunier, Ondine Becquart, et al.. Clinical Relevance of Liquid Biopsy in Melanoma and Merkel Cell Carcinoma. Cancers, 2020, 12 (4), pp.960. ⟨10.3390/cancers12040960⟩. ⟨hal-03257721⟩
22 Consultations
75 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More